Antimycobacterials Flashcards
1
Q
Match the clinical manifestations with the specific mycobacterium:
- Tuberculosis:
- Leprosy (Hansen’s Disease):
- Pulmonary; intestinal mucosa & lymph nodes:
A
- M. tuberculosis
- M. Leprae
- M. avium-intracellulare (MAI or MAC)
2
Q
Why are mycobacteria challenging to treat?
A
-
Cells grow very slowly
- Difficult to kill
- Difficult to grow, identify, and do susceptibility testing
- Requires very lengthy therapy
- Chronic disease
- Intracellular forms
-
Spontaneous resistance
- Requires multi-drug therapy
3
Q
Drugs Used in TB Therapy (5):
A
- Isoniazid
- Rifampin
- Ethambutol
- Pyrazinamide
- Streptomycin
4
Q
Isoniazid (INH™; Nydrazid®):
- Mechanism:
- Resistance:
A
Mechanism
-
Bactericidal for actively growing bacilli
- bacteriostatic for “resting cells”
-
Inhibits synthesis of mycolic acids
- prodrug which is activated by the catalase-peroxidase (KatG protein) of the tubercle bacillus
- targets the enoyl-acyl carrier protein reductase (InhA protein)
Restistance
- result from mutations in KatG or InhA
5
Q
Isoniazid:
- Use:
- Absorption/Excretion:
- Adverse Effects:
A
Use
- Most important primary TB drug
- all patients with INH-sensitive strains should receive INH if possible
- For treatment, always given in combination with other agents
Absoprtion/Excretion
- **N-acetylation: **under genetic control (polymorphisms)
Adverse Effects
-
Neurotoxicity, esp. peripheral neuritis
- significantly improved with B6 administration
- Hepatotoxicity (10-20%)
6
Q
Rifampin (Rifadin®, Rimactane®):
- Mechanism:
- Adverse Effects:
A
Mechanism
- Inhibits bacterial DNA-dependent RNA polymerase, ⇒ suppressing RNA synthesis
- Bactericidal
Adverse Effects
- Hepatotoxicity
- Potent inducer of multiple CYPs ⇒ increasing metabolism of other drugs
- Orange-red color
7
Q
Ethambutol (Myambutol®):
- Mechanism:
- Adverse Effects:
A
Mechanism
- Interferes with arabinosyl transferase, blocking cell wall synthesis
- Tuberculostatic
Adverse Effects
- Not hepatotoxic
- Optic neuritis (5-15%)
8
Q
Pyrazinamide (PZA):
A
-
Blocks mycolic acid synthesis
- inhibits fatty acid synthase I
- bactericidal
- Well-absorbed
- widely distributed, incl. CSF
-
Hepatic damage
- esp. when combined w/ Rifampin
9
Q
Streptomycin:
- Mechanism:
- Use:
- Adverse Effects:
A
-
Mechanism
- binds to several ribosomal sites
- stops initiation
- causes mRNA misreading
- bactericidal
-
Use
- Usually reserved for the most serious forms of TB
-
Adverse Effects
- Ototoxicity (affecting both balance and hearing)
- Nephrotoxicity
10
Q
Examples of Multi-Drug Regimens for Treating Active TB:
A
ALWAYS use at least two drugs
- Short-Course Therapy for Uncomplicated Pulmonary TB
- Disseminated TB
- Use of 4 or More Drugs
- known exposure to drug-resistant strains
- severe or disseminated disease
11
Q
Eradication Vs. Stasis Of TB Infections:
A
-
Bacteriostatic
- Intracellular and Extracellular
- ethambutol
- p-aminosalicylic acid
- Intracellular and Extracellular
-
Bactericidal
-
Intracellular and Extracellular
- isoniazid
- rifampin
- pyarzinamide
- Extracellular
- streptomycin
-
Intracellular and Extracellular
12
Q
“Atypical” Mycobacterial Infections:
A
- MAC = M. avium-intracellulare complex
- MAC is less fatal than TB, so if find AFB, institute anti-TB regimen until agent is identified
13
Q
Drugs Used to Treat “Atypical” Mycobacterial Infections:
A
- Rifabutin
- Clarithromycin
- Azithromycin
14
Q
Rifabutin:
A
- Rifampin analog
- single-agent prophylaxis of M. avium-intracellulare (MAC) in AIDS patients
- multi-drug treatment of MAC
-
Toxicities:
- Similar to rifampin but less frequent
- Drug interactions similar to rifampin
- less potent CYP inducer
15
Q
Clarithromycin, azithromycin:
A
- Part of multi-drug regimen for treatment of M. avium-intracellulare in AIDS patients
- Also used for:
- MAC prophylaxis
- Bactericidal